

Pharmacy BULLETIN BOARD

Hospital Issue ■ Monday May 26, 2014.

UriSec® emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.

Product	Sizes	Odan Code	Kohl & Frisch Code	McKesson Code	McMahon Code
UriSec® 10% Cream NPN 80005397	75 g	38075	32617	513085	26638401
	120 g	38045	32618	513341	26638301
UriSec® 12% Lotion NPN 00514896	250 mL	230J	48909	115493	26623101
	120 g	220Q	46312	115444	26623201
UriSec® 22% Cream NPN 00396125	225 g	220C	-	153486	26537801
	454 g	220R	46309	848549	26632301
	15 g	45014	114939	003743	-
UriSec® 40 Cream NPN 80005531	30 g	45028	32606	799437	27127401
	100 g	45067	32616	799494	26640001

UriSec® products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com



UriSec® is a registered trademark of Odan Laboratories Ltd.



MARKHAM, ON: Newly published data is giving Canadian patients suffering from mild to moderate forms of idiopathic pulmonary fibrosis (IPF) hope that publicly-funded access to the only approved treatment option may soon be a reality. The Phase 3 ASCEND Study: A Randomized, Double-Blind, Placebo-Controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF), was presented at the 2014 International Conference of the American Thoracic Society (ATS) in San Diego, California, and concurrently published in *The New England Journal of Medicine*. The much anticipated study results confirm the proven efficacy and safety of Esbriet® (pirfenidone), the first and only treatment approved in Canada for IPF – a rare, progressive and ultimately fatal lung disease.

FROM THE NEWSWIRE

THORNHILL, ON: Galderma Canada Inc. has announced that ONRELTEA™ topical gel (Brimonidine gel 0.33%) has been approved by Health Canada and is now available for Canadian patients 18 and older to treat the facial erythema (redness) of rosacea. ONRELTEA is the first and only Health Canada-approved topical prescription specifically designed to treat the facial redness of rosacea.

NEW GLASGOW, NS: On behalf of the Honourable Rona Ambrose, Minister of Health, the Honourable Peter MacKay, Regional Minister for Nova Scotia and Minister of Justice and Attorney General for Canada, has announced \$16.1 million in federal funding over three years to help prevent and reduce illicit and prescription drug abuse among youth ages 10 to 24.

MONTREAL: Laurent Pharmaceuticals Inc. has announced that the Research Institute of the McGill University Health Centre (RI-MUHC) has started enrolling patients in an investigator-initiated clinical trial evaluating the safety, tolerability and pharmacokinetics of a novel oral formulation of Fenretinide in adult subjects with Cystic Fibrosis (CF) and *Pseudomonas aeruginosa* lung colonization. The study will be conducted at the Montreal Chest Institute at the MUHC in Montréal, with financial support from McGill University, MSBi Valorisation and Laurent Pharmaceuticals.

MONTREAL: AbbVie filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including patients with cirrhosis. The NDS is supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date, with six Phase III studies that included more than 2,300 patients in over 25 countries.

OTTAWA: Health Canada has launched a six week consultation period, from May 22, 2014 - July 5, 2014, to hear from patients, healthcare providers, and other Canadians on the current approach to drug shortage notification via www.drugshortages.ca. This industry-led website was launched in 2012 at the request of the Minister of Health to provide a go-to source of information about actual and anticipated shortages of medications.

OTTAWA: Health Canada is informing patients about the potential risk of complications associated with transvaginal implantation of surgical mesh devices for the treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI). Although many women treated with these devices have had good outcomes, Health Canada continues to receive reports of complications.